Brokerages expect Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) to announce sales of $280,000.00 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Galmed Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $250,000.00 and the highest estimate coming in at $300,000.00. Galmed Pharmaceuticals posted sales of $270,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 3.7%. The company is scheduled to issue its next quarterly earnings results on Thursday, March 22nd.
According to Zacks, analysts expect that Galmed Pharmaceuticals will report full-year sales of $280,000.00 for the current fiscal year, with estimates ranging from $800,000.00 to $1.10 million. For the next financial year, analysts forecast that the business will report sales of $980,000.00 per share, with estimates ranging from $550,000.00 to $1.20 million. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that follow Galmed Pharmaceuticals.
Galmed Pharmaceuticals (NASDAQ:GLMD) last issued its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.04. Galmed Pharmaceuticals had a negative return on equity of 167.83% and a negative net margin of 1,242.49%.
Galmed Pharmaceuticals (GLMD) opened at $10.18 on Monday. The firm has a market capitalization of $129.63, a PE ratio of -9.17 and a beta of 2.42. Galmed Pharmaceuticals has a 1-year low of $3.90 and a 1-year high of $12.22.
An institutional investor recently raised its position in Galmed Pharmaceuticals stock. 683 Capital Management LLC lifted its position in shares of Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) by 9.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 549,295 shares of the biopharmaceutical company’s stock after buying an additional 49,295 shares during the period. 683 Capital Management LLC owned about 4.31% of Galmed Pharmaceuticals worth $5,021,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.80% of the company’s stock.
WARNING: “Zacks: Brokerages Anticipate Galmed Pharmaceuticals Ltd (GLMD) Will Announce Quarterly Sales of $280,000.00” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/02/05/zacks-brokerages-anticipate-galmed-pharmaceuticals-ltd-glmd-will-announce-quarterly-sales-of-280000-00.html.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.